Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
  • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/348—Cannabaceae
  • A61K36/3482—Cannabis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
  • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
  • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01D—SEPARATION
  • B01D11/00—Solvent extraction
  • B01D11/02—Solvent extraction of solids
  • B01D11/0203—Solvent extraction of solids with a supercritical fluid
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01D—SEPARATION
  • B01D11/00—Solvent extraction
  • B01D11/02—Solvent extraction of solids
  • B01D11/0288—Applications, solvents
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01D—SEPARATION
  • B01D9/00—Crystallisation
  • B01D9/0004—Crystallisation cooling by heat exchange
  • B01D9/0013—Crystallisation cooling by heat exchange by indirect heat exchange

Definitions

• the present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures.
• CBD cannabidiol
• the patients suffering from focal seizures are children and young adults.
• CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types.
• CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.
• the etiologies of patients which suffer from focal seizures with impairment include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities.
• the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised.
• the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1 %.
• the CBD may be a synthetically produced CBD.
• the CBD may be used concomitantly with one or more other anti-epileptic drugs (AED).
• AED anti-epileptic drugs
• the CBD may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form.
• the CBD is formulated for administration separately, sequentially or simultaneously it may be provided as a kit or together with instructions to administer the one or more components in the manner indicated. It may also be used as the sole medication, i.e. as a monotherapy.
• Epilepsy occurs in approximately 1 % of the population worldwide, (Thurman et al., 201 1) of which 70% are able to adequately control their symptoms with the available existing anti-epileptic drugs (AED). However, 30% of this patient group, (Eadie et al. , 2012), are unable to obtain seizure freedom using the AED that are available and as such are termed as suffering from intractable or "treatment-resistant epilepsy” (TRE).
• TRE treatment-resistant epilepsy
• Intractable or treatment-resistant epilepsy was defined in 2009 by the International League against Epilepsy (ILAE) as "failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom" (Kwan et ai , 2009).
• ILAE International League against Epilepsy
• Childhood epilepsy is a relatively common neurological disorder in children and young adults with a prevalence of approximately 700 per 100,000. This is twice the number of epileptic adults per population.
• the main symptom of epilepsy is repeated seizures.
• an investigation into the type of seizures that the patient is experiencing is undertaken.
• Clinical observations and electroencephalography (EEG) tests are conducted and the type(s) of seizures are classified according to the ILAE classification described below and in Figure 1.
• Focal (partial) seizures where the seizure originates within networks limited to only one hemisphere, are also split into sub-categories.
• the seizure is characterized according to one or more features of the seizure, including aura, motor, autonomic and awareness / responsiveness.
• a seizure begins as a localized seizure and rapidly evolves to be distributed within bilateral networks this seizure is known as a Bilateral convulsive seizure, which is the proposed terminology to replace Secondary Generalized Seizures (generalized seizures that have evolved from focal seizures and are no longer remain localized).
• focal seizures where the subjects awareness / responsiveness is altered are referred to as focal seizures with impairment and focal seizures where the awareness or responsiveness of the subject is not impaired are referred to as focal seizures without impairment.
• Focal seizures may occur in epilepsy syndromes including: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities.
• Epileptic syndromes often present with many different types of seizure and identifying the types of seizure that a patient is suffering from is important as many of the standard AED's are targeted to treat or are only effective against a given seizure type / subtype.
• Dravet syndrome One such childhood epilepsy is Dravet syndrome. Onset of Dravet syndrome almost always occurs during the first year of life with clonic and tonic-clonic seizures in previously healthy and developmental ⁇ normal infants (Dravet, 201 1). Symptoms peak at about five months of age. Other seizures develop between one and four years of age such as prolonged focal dyscognitive seizures and brief absence seizures.
• Dravet patients may also experience atypical absence seizures, myoclonic absence seizures, atonic seizures and non-convulsive status epilepticus.
• Seizures progress to be frequent and treatment-resistant, meaning that the seizures do not respond well to treatment. They also tend to be prolonged, lasting more than 5 minutes. Prolonged seizures may lead to status epilepticus, which is a seizure that lasts more than 30 minutes, or seizures that occur in clusters, one after another.
• Prognosis is poor and approximately 14% of children die during a seizure, because of infection, or suddenly due to uncertain causes, often because of the relentless neurological decline. Patients develop intellectual disability and life-long ongoing seizures. Intellectual impairment varies from severe in 50% patients, to moderate and mild intellectual disability each accounting for 25% of cases.
• Dravet syndrome There are currently no FDA approved treatments specifically indicated for Dravet syndrome.
• the standard of care usually involves a combination of the following anticonvulsants: clobazam, clonazepam, levetiracetam, topiramate and valproic acid.
• stiripentol was granted an Orphan Designation for the treatment of Dravet syndrome in 2008; however, the drug is not FDA approved.
• Potent sodium channel blockers used to treat epilepsy actually increase seizure frequency in patients with Dravet Syndrome.
• the most common are phenytoin, carbamazepine, lamotrigine and rufinamide.
• Management may also include a ketogenic diet, and physical and vagus nerve stimulation.
• a ketogenic diet and physical and vagus nerve stimulation.
• many patients with Dravet syndrome are treated with anti-psychotic drugs, stimulants, and drugs to treat insomnia.
• the first line treatment for focal seizures are AED such as carbamezapine or lamotrigine. Levetiracetam, oxycarbamezapine or sodium valproate are also considered to be of use. A combination of these medicaments may be required in order to treat focal seizures.
• Vigabatrin GABA Secondarily generalized tonic- clonic seizures
• Valproic acid GABA / Sodium channel First-line treatment for tonic- clonic seizures, absence seizures and myoclonic seizures
• CBD non-psychoactive cannabinoid cannabidiol
• Maa and Figi (2014) discuss the case for medical marijuana in epilepsy and discuss the positive treatment of a girl Charlotte with Dravet syndrome who experienced frequent bouts of febrile and afebrile status epilepticus as well as tonic, tonic-clonic and myoclonic seizures (generalised seizures). She was given an extract from a cannabis plant dubbed "Charlotte's Web" which according to the suppliers, CW Botanicals, disclose that their extracts are rich in terpenes and contain from 10 to 200 times the amount found in other proprietary plants. In other words the suggestion is that the efficacy is based on a combination of CBD and the terpenes present in their extracts.
• the document recognizes the effectiveness of an anti-seizure medication may be dependent upon: the drug itself, including CBD, (see Table 3); the epilepsy syndrome type (Table 2); and the seizure type (Table 2).
• That of the seizure types studied ranged from 44% responder rate for atonic seizures to 17% responder rates in tonic seizures, amongst the seven seizures types reviewed.
• CBD is particularly effective in the treatment of focal seizures in Dravet syndrome patients, particularly children and more particularly those which are resistant to existing treatments.
• Cannabidiol for use in the treatment of focal seizures in Dravet Syndrome.
• the focal seizures are focal seizures with impairment.
• the Dravet Syndrome is treatment-resistant.
• the CBD is for use in combination with one or more concomitant anti-epileptic drugs (AED).
• AED concomitant anti-epileptic drugs
• the CBD is present as a highly purified extract of cannabis which comprises at least 98% (w/w) CBD.
• the extract comprises less than 0.15% THC. More preferably the extract further comprises up to 1 % CBDV.
• the CBD is present as a synthetic compound.
• the one or more AED is selected from the group consisting of: carbamezapine, clobazam, clonazepam, clonidine, clorazepate, desmethylclobazam, diazepam, ethosuximide, felbamate, ketogenic diet, lacosamide, lamotrigine, levetiracetam, lorazepam, midazolam, N-desmethylclobazam, nordiazepam, oxycarbamezapine, perampanel, phenobarbital, phenytoin, pregabalin, rufinamide, stiripentol, topiramate, trazodone, vagus nerve stimulation, valproic acid, vigabatrin, and zonisamide.
• the number of different anti-epileptic drugs that are used in combination with the CBD is reduced.
• the dose of anti-epileptic drugs that are used in combination with the CBD is reduced.
• the dose of CBD is greater than 5 mg/kg/day.
• a dose of greater than 75mg of CBD per day would be provided.
• Doses greater than 5mg/kg/day such as greater than 10/mg/kg/day, greater than 15 mg/kg/day, greater than 20mg/kg/day and greater than 25 mg/kg/day are also envisaged to be effective.
• a method of treating focal seizures in Dravet Syndrome comprising administering cannabidiol (CBD) to a subject.
• CBD cannabidiol
• the subject is a human.
• compositions for use in the treatment of epilepsy characterised by focal seizures in Dravet syndrome comprising cannabidiol (CBD), a solvent, a co-solvent, a sweetener, and a flavouring.
• CBD cannabidiol
• the solvent is sesame oil
• the co-solvent is ethanol
• the sweetener is sucralose
• the flavouring is strawberry flavour
• the CBD is present at a concentration of between 25/mg/ml and 100 mg/ml, namely 50mg/ml and 75 mg/ml.
• the composition comprises cannabidiol (CBD) at a concentration of between 25 to 100 mg/ml, ethanol at a concentration of 79 mg/ml, sucralose at a concentration of 0.5 mg/ml, strawberry flavouring at a concentration of 0.2 mg/ml and sesame oil q.s. to 1.0ml.
• CBD cannabidiol
• composition be administered as an oral liquid solution.
• Other modes of administration including solids, semi-solids, gels, sprays, aerosols, inhalers, vaporisers, enemas and suppositories are alternative administration forms.
• Such medicaments could be administered via the oral, buccal, sublingual, respiratory, nasal and distal rectum route.
• CBDA Cannabidiolic acid
• CBDV Cannabidivarin
• CBDVA Cannabidivarinic acid
• Phytocannabinoids Phytocannabinoids; Endocannabinoids and Synthetic cannabinoids (which may be novel cannabinoids or synthetically produced phytocannabinoids or endocannabinoids).
• phytocannabinoids are cannabinoids that originate from nature and can be found in the cannabis plant.
• the phytocannabinoids can be isolated from plants to produce a highly purified extract or can be reproduced synthetically.
• “Highly purified cannabinoid extracts” are defined as cannabinoids that have been extracted from the cannabis plant and purified to the extent that other cannabinoids and non- cannabinoid components that are co-extracted with the cannabinoids have been substantially removed, such that the highly purified cannabinoid is greater than or equal to 98% (w/w) pure.
• Synthetic cannabinoids are compounds that have a cannabinoid or cannabinoid-like structure and are manufactured using chemical means rather than by the plant.
• Phytocannabinoids can be obtained as either the neutral (decarboxylated form) or the carboxylic acid form depending on the method used to extract the cannabinoids. For example it is known that heating the carboxylic acid form will cause most of the carboxylic acid form to decarboxylate into the neutral form.
• Treatment-resistant epilepsy (TRE) or “intractable epilepsy” is defined as per the ILAE guidance of 2009 as epilepsy that is not adequately controlled by trials of one or more AED.
• Childhood epilepsy refers to the many different syndromes and genetic mutations that can occur to cause epilepsy in childhood. Examples of some of these are as follows:
• Dravet Syndrome Myoclonic-Absence Epilepsy; Lennox-Gastaut syndrome; Generalized Epilepsy of unknown origin; CDKL5 mutation; Aicardi syndrome; bilateral polymicrogyria;
• FIRES febrile infection related epilepsy syndrome
• benign rolandic epilepsy juvenile myoclonic epilepsy
• infantile spasm West syndrome
• Landau-Kleffner syndrome The list above is non-exhaustive as many different childhood epilepsies exist.
• “Focal Seizures” are defined as seizures which originate within networks limited to only one hemisphere. What happens during the seizure depends on where in the brain the seizure happens and what that part of the brain normally does.
• the terms "50% responded and "50% reduction in seizure” are both terms used in clinical studies. In the present application the terms define the percentage of subjects that experienced a greater than or equal to 50% reduction in the number of seizures during treatment with CBD in comparison to the number experienced during the baseline period before the CBD was administered.
• the drug substance used in the trials is a liquid carbon dioxide extract of high-CBD containing chemotypes of Cannabis sativa L. which had been further purified by a solvent crystallization method to yield CBD.
• the crystallisation process specifically removes other cannabinoids and plant components to yield greater than 98% CBD.
• Cannabis sativa L. plants are grown, harvested, and processed to produce a botanical extract (intermediate) and then purified by crystallization to yield the CBD (drug substance).
• the plant starting material is referred to as Botanical Raw Material (BRM); the botanical extract is the intermediate; and the active pharmaceutical ingredient (API) is CBD, the drug substance.
• BRM Botanical Raw Material
• API active pharmaceutical ingredient
• the purity of the CBD drug substance achieved is greater than 98%.
• the other cannabinoids which may occur in the extract are: CBDA, CBDV, CBD-C4 and THC.
• Distinct chemotypes of Cannabis sativa L. plant have been produced to maximize the output of the specific chemical constituents, the cannabinoids.
• One type of plant produces predominantly CBD. Only the (-)-trans isomer occurs naturally. Furthermore during purification the stereochemistry of CBD is not affected.
• Decarboxylation of CBDA to CBD was carried out using a large Heraeus tray oven.
• the decarboxylation batch size in the Heraeus is approximately 15 Kg. Trays were placed in the oven and heated to 105°C; the BRM took 96.25 minutes to reach 105 °C. Held at 105°C for 15 Minutes. Oven then set to 150°C; the BRM took 75.7 minutes to reach 150°C; BRM held at 150°C for 130 Minutes. Total time in the oven was 380 Minutes, including 45 minutes cooling and 15 Minutes venting.
• Extraction No 1 was performed using liquid C0 2 at 60 bar / 10°C to produce botanical drug substance (BDS).
• the crude CBD BDS was winterised in Extraction No 2 under standard conditions (2 volumes of ethanol at minus 20°C for around 50 hours). The precipitated waxes were removed by filtration and the solvent evaporated using the rotary evaporator (water bath up to 60°C) to yield the BDS, which was then used for crystallisation to produce the test material..
• the dried product was stored in a freezer at minus 20°C in a pharmaceutical grade stainless steel container, with FDA food grade approved silicone seal and clamps. Production of the Drug Product
• the drug product is presented as an oral solution.
• the oral solution presentation contains 25mg/ml or 100mg/ml CBD, with the excipients sesame oil, ethanol, sucralose and flavouring. Two product strengths are available to allow dose titration across a wide dose range.
• the 25 mg/ml solution is appropriate at lower doses and the 100 mg/ml solution at higher doses.
• the drug substance, CBD is insoluble in water. Sesame oil was selected as an excipient to solubilize the drug substance.
• a sweetener and fruit flavouring are required to improve palatability of the sesame oil solution.
• Ethanol was required to solubilize the sweetener and the flavouring.
• composition can be substantially equivalent, by which is meant the functional ingredients can vary from the qualitative composition specified in Table 6 by an amount of up to
• Example 1 describes the use of a highly purified cannabis extract comprising cannabidiol (CBD).
• CBD cannabidiol
• Cannabidiol is the most abundant non-psychoactive cannabinoid in the selected chemovar. Previous studies in animals have demonstrated that CBD has
• Example 1 describes data produced in an expanded access treatment program in children with TRE.
• EXAMPLE 1 EFFICACY OF CANNABIDIOL REDUCING FOCAL SEIZURES IN CHILDREN AND YOUNG ADULTS WITH INTRACTABLE EPILEPSY Materials and Methods
• CBD cannabidiol
• the epileptic syndromes that these patients suffered from were as follows: Lennox- Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities.
• the patients then received a highly purified CBD extract (greater than 98% CBD w/w) in sesame oil, of known and constant composition, at a dose of 5 mg/kg/day in addition to their baseline anti-epileptic drug (AED) regimen.
• AED anti-epileptic drug
• the daily dose was gradually increased by 2 to 5mg/kg increments until intolerance occurred or a maximum dose of 25 mg/kg/day was achieved.
• the patients on the study were all taking at least one concomitant AED. These included: carbamezapine, clobazam, clonazepam, clonidine, clorazepate, desmethylclobazam, diazepam, ethosuximide, felbamate, ketogenic diet, lacosamide, lamotrigine, levetiracetam, lorazepam, midazolam, N-desmethylclobazam, nordiazepam, oxycarbamezapine, perampanel, phenobarbital, phenytoin, pregabalin, rufinamide, stiripentol, topiramate, trazodone, vagus nerve stimulation, valproic acid, vigabatrin, and zonisamide. Results
• Table 7 shows that after 3 months of therapy, a remarkable 63% of patients had an equal to or greater than >50% reduction in focal seizures, these data infer that the CBD is very effective at reducing this type of seizure.
• EXAMPLE 2 EFFICACY OF CANNABIDIOL REDUCING FOCAL SEIZURES WITH IMPAIRMENT IN CHILDREN AND YOUNG ADULTS WITH INTRACTABLE EPILEPSY
• CBD cannabidiol
• the epileptic syndromes that these patients suffered from were as follows: Lennox- Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities.
• the patients then received a highly purified CBD extract (greater than 98% CBD w/w) in sesame oil, of known and constant composition, at a dose of 5 mg/kg/day in addition to their baseline anti-epileptic drug (AED) regimen.
• AED anti-epileptic drug
• Table 8 shows that after 3 months of therapy, a remarkable 65% of patients had an equal to or greater than >50% reduction in focal seizures with impairment, these data infer that the CBD is very effective at reducing this type of seizure.
• Dravet C The core Dravet syndrome phenotype. Epilepsia. 2011 Apr;52 Suppl 2:3-9.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Neurosurgery (AREA)
• Pain & Pain Management (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Alternative & Traditional Medicine (AREA)
• Biotechnology (AREA)
• Botany (AREA)
• Medical Informatics (AREA)
• Thermal Sciences (AREA)
• Physics & Mathematics (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Crystallography & Structural Chemistry (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Plant Substances (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=53784899

Family Applications (1)

Country Status (8)

Cited By (26)

Families Citing this family (64)

Citations (3)

Family Cites Families (207)

• 2015
  • 2015-06-17 GB GB1510664.4A patent/GB2539472A/en not_active Withdrawn
• 2016
  • 2016-06-16 EP EP16731281.8A patent/EP3310390A1/en not_active Withdrawn
  • 2016-06-16 HK HK18112785.4A patent/HK1253580A1/zh unknown
  • 2016-06-16 EP EP21203376.5A patent/EP3984531A1/en active Pending
  • 2016-06-16 US US15/183,947 patent/US10709671B2/en active Active
  • 2016-06-16 MX MX2021003331A patent/MX2021003331A/es unknown
  • 2016-06-16 WO PCT/GB2016/051792 patent/WO2016203239A1/en not_active Ceased
  • 2016-06-16 AU AU2016278088A patent/AU2016278088B2/en active Active
  • 2016-06-16 MX MX2017016212A patent/MX381089B/es unknown
  • 2016-06-16 JP JP2017565998A patent/JP6983076B2/ja active Active
• 2017
  • 2017-12-13 MX MX2022015027A patent/MX2022015027A/es unknown
• 2020
  • 2020-06-04 US US16/893,018 patent/US11357741B2/en active Active
• 2021
  • 2021-11-17 AU AU2021269374A patent/AU2021269374B2/en active Active
  • 2021-11-22 JP JP2021189417A patent/JP2022033807A/ja active Pending
• 2022
  • 2022-05-13 US US17/744,224 patent/US12064399B2/en active Active
• 2024
  • 2024-07-02 US US18/762,588 patent/US20240350428A1/en not_active Abandoned

Patent Citations (4)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events